[Dr.Vad]

Уважаемый Алексей!

Цитата: "От чего не помог Вам офлоксин? От бактериального вагиноза? Так и не должен помогать."

Позвольте с Вами не согласиться: офлоксацин может помогать при БВ, хотя его эффективность значительно ниже, чем у метронидазола.

Int J STD AIDS. 1992 May-Jun;3(3):204-7.

Comparison of ofloxacin and metronidazole for the treatment of bacterial vaginosis.

Nayagam AT, Smith MD, Ridgway GL, Allason-Jones E, Robinson AJ, Stock J.

Department of Genitourinary Medicine, University College Hospital, London.

The efficacy and safety of ofloxacin, 200 mg twice daily for 7 days, was compared with metronidazole, 400 mg twice daily for 7 days, for the treatment of bacterial vaginosis (BV). Diagnosis of BV was confirmed by at least 3 of the following 4 criteria: the presence of an abnormal vaginal discharge on examination, clue cells on microscopy of vaginal specimens, vaginal pH greater than 5.0 and a positive amine test. Vaginal specimens were examined for Mobiluncus spp, analysed for the succinate/lactate (S/L) ratio and cultured for Trichomonas vaginalis, Gardnerella vaginalis, Bacteroides spp. and Mycoplasma hominis. Patients were reviewed on completion of treatment (visit 2) and 14 days later (visit 3). The diagnosis of BV was accepted in 119 of 149 patients recruited, 60 of whom received treatment with ofloxacin and 59 received metronidazole. Sixty-two patients, 31 in each treatment group, completed the study. Diagnostic cure at visit 2 was significantly better in the metronidazole group with cure rates of 56% (metronidazole) vs 23% (ofloxacin) (P = 0.001); this was associated with higher eradication rates for G. vaginalis (100% vs 56%) and Bacteroides spp. (97% vs 49%). There were no significant differences between the two groups in clinical cure at either visit 2 or 3 or in diagnostic cure at visit 3. Both treatments were well tolerated. We conclude that metronidazole is likely to remain the first choice of treatment for BV but ofloxacin offers a safe and effective alternative.

Randomized Controlled Trial


Sex Transm Dis. 1993 Sep-Oct;20(5):262-4.

Comparative evaluation of ofloxacin and metronidazole in the treatment of bacterial vaginosis.

Covino JM, Black JR, Cummings M, Zwickl B, McCormack WM.

Department of Medicine, State University of New York Health Science Center at Brooklyn 11203.

BACKGROUND AND OBJECTIVES: The epidemiology and etiology of bacterial vaginosis is poorly understood. Many antimicrobial agents have been studied and suggested as treatment alternatives for this infection. Fluoroquinolones have in vitro activity against some of the organisms associated with bacterial vaginosis and may provide another treatment option. STUDY DESIGN: Women who presented with symptomatic bacterial vaginosis were randomly assigned to receive either oral ofloxacin 300 mg twice a day or oral metronidazole 500 mg twice a day for seven days. Twenty-seven of the 31 patients who were enrolled in this double-blinded study were evaluable. RESULTS: Fourteen women received ofloxacin. At follow-up, four had no residual symptoms, seven noted a reduction in symptoms, and three had no change in symptoms. Eight (57%) of the 14 women who received ofloxacin had secretions at follow-up that satisfied the criteria for the diagnosis of bacterial vaginosis. Thirteen women received metronidazole. Nine had no residual symptoms and four noted a reduction in symptoms. Eleven (85%) of the 13 women had normal vaginal secretions and two (15%) had secretions that were improved. None of the women who received metronidazole had secretions at follow-up that met the criteria for the diagnosis of bacterial vaginosis. CONCLUSION: We conclude that ofloxacin is less effective than metronidazole in the treatment of bacterial vaginosis.

Multicenter Study
Randomized Controlled Trial